CD8A and neoplasm: In particular, HH pathway inhibition is able to reduce the number of tumor-associated monocytes and macrophages, reverse the CD8+ T cell tumor immune exclusion and increase the influx of NK cells into the TME, rendering the tumor responsive to anti-PDL1 treatment [99].